ISLAMABAD: The Competition Commission of Pakistan (CCP) has approved the acquisition of two pharmaceutical products from Tokyo-based Eisai by Hilton Pharma. The acquisition includes the rights to manufacture and commercialise the drugs Methycobal and Myonal in Pakistan.

The transaction involves the transfer of trademarks, know-how and records related to these products under an asset purchase agreement signed between the two companies. This agreement aims to facilitate the production and distribution of these medications within Pakistan.

Hilton Pharma, established in 1989, has been manufacturing and distributing medicinal products in the country. The company is authorised by the Drug Regulatory Authority of Pakistan to produce pharmaceutical items.

Eisai is a global leader in pharmaceutical research, development, manufacturing, and marketing, with a strong focus on prescription medicines.

Published in Dawn, June 26th, 2024